Achieve Life Sciences - ACHV Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1 year price objectives for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $8.00 to $24.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 571.8% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.

Achieve Life Sciences' stock was trading at $7.78 at the beginning of the year. Since then, ACHV stock has decreased by 66.8% and is now trading at $2.58.
View the best growth stocks for 2022 here.

Achieve Life Sciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 334,100 shares, an increase of 11.7% from the October 31st total of 299,200 shares. Based on an average daily volume of 60,400 shares, the short-interest ratio is currently 5.5 days. Approximately 5.4% of the company's stock are short sold.
View Achieve Life Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our ACHV earnings forecast.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($1.09) by $0.38. During the same quarter last year, the firm earned ($1.14) earnings per share.

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Achieve Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Long Focus Capital Management LLC (3.18%), Perkins Capital Management Inc. (2.25%), Citadel Advisors LLC (0.36%), Royal Bank of Canada (0.35%), Group One Trading L.P. (0.00%) and Raymond James & Associates (0.18%).
View institutional ownership trends.

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACHV stock can currently be purchased for approximately $2.58.

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $24.97 million. The biopharmaceutical company earns $-33,150,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.